Skip to main content

Advertisement

SpringerLink
Log in

LDL reduction: How low should we go and is it safe?

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

High-dose statin therapy or combination statin treatment is necessary for most patients to achieve aggressive lowdensity lipoprotein cholesterol goals. Adding ezetimibe or bile acid sequestrants appears unlikely to increase the risk of myopathy. Although the combination of niacin or fenofibrate with moderate-dose statins appears to be reasonably safe, the safety of combination with highdose statins has yet to be determined. To enhance patient outcomes, attention must be paid to characteristics that predict muscle and hepatic statin toxicity when considering using high-dose statin or combination statin therapy

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.

    Article  PubMed  CAS  Google Scholar 

  2. Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855–1862.

    Article  PubMed  CAS  Google Scholar 

  3. Grundy SM, Cleeman JI, Merz CNB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  4. Smith SC Jr, Allen J, Blair SN, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363–2372

    Article  PubMed  Google Scholar 

  5. Robinson JG, Stone NJ: Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol 2006, 98:1405–1408.

    Article  PubMed  Google Scholar 

  6. Law M, Wald N, Morris J: Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003, 7:1–94.

    PubMed  CAS  Google Scholar 

  7. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425–1435.

    Article  PubMed  CAS  Google Scholar 

  8. Crestor (rosuvastatin calcium) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2007. Available at http://www.astrazeneca-us.com/pi/crestor.pdf. Accessed February 2007.

  9. Lipitor (atorvastatin calcium) [package insert]. New York, NY: Pfizer Inc.; 2007. Available at http://www.pfizer.com/files/products/uspi_lipitor.pdf. Accessed June 2008.

  10. Vytorin (simvastatin/ezetimibe) [package insert]. White-house Station, NJ, and Kenilworth, NJ: Merck-Schering Plough Pharmaceuticals; 2008. Available at http://www.vytorin.com/vytorin/shared/documents/vytorin_pi.pdf. Accessed June 2008.

  11. Jones PH, Davidson MH, Stein EA, et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92:152–160.

    Article  PubMed  CAS  Google Scholar 

  12. Robinson J, Davidson M: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 2006, 4:461–476.

    Article  PubMed  CAS  Google Scholar 

  13. Advicor (extended-release niacin) [package insert]. Abbott Park, IL: Abbott Laboratories; 2007. Available at http://www.rxabbott.com/pdf/advicor.pdf. Accessed June 2008.

  14. Simcor (niacin extended-release/simvastatin) [package insert]. Abbott Park, IL: Abbott Laboratories; 2008. Available at http://rxabbott.com/pdf/simcor_pi.pdf. Accessed May 5, 2008.

  15. Welchol (colesevelam hydrochloride) [package insert]. Parsippany, NJ: Daiichi Sankyo; 2005. Available at http://www.welchol.com/pdf/Welchol_PI.pdf. Accessed May 2008.

  16. Wagner AM, Jorba O, Bonet R, et al.: Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003, 88:3212–3217.

    Article  PubMed  Google Scholar 

  17. Athyros VG, Papageorgiou AA, Athyrou VV, et al.: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198–1202.

    Article  PubMed  CAS  Google Scholar 

  18. Durrington PN, Tuomilehto J, Hamann A, et al.: Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diab Res Clin Pract 2004, 64:137–151.

    Article  CAS  Google Scholar 

  19. Kastelein JJP, Akdim F, Stroes ESG, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443.

    Article  PubMed  CAS  Google Scholar 

  20. Smilde TJ, van Wissen S, Awollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577–581.

    Article  PubMed  CAS  Google Scholar 

  21. Underhill HR, Yuan C, Zhao X-Q, et al.: Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008, 155:584.e1–584.e5.

    Article  Google Scholar 

  22. Johnson HM, Douglas PS, Srinivasan SR, et al.: Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke 2007, 38:900–905.

    Article  PubMed  Google Scholar 

  23. van Wissen S, Smilde TJ, Trip MD, et al.: Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005, 95:264–266.

    Article  PubMed  Google Scholar 

  24. Robinson JG: Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res 2008, 2008:891425.

  25. Kastelein JJ, van der Steeg WA, Holme I, et al.: Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117:3002–3009.

    Article  PubMed  CAS  Google Scholar 

  26. Robinson JG, Davidson MH: Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. Future Lipidol 2007, 2:285–301.

    Article  CAS  Google Scholar 

  27. Ford ES, Ajani UA, Croft JB, et al.: Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007, 356:2388–2398.

    Article  PubMed  CAS  Google Scholar 

  28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. National Cholesterol Education Panel [no authors listed]. Circulation 2002, 106:3143–3421.

  29. Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.

    Article  PubMed  CAS  Google Scholar 

  30. Davidson M, Robinson JG: Safety of aggressive lipid management. J Am Coll Cardiol 2007, 49:1753–1762.

    Article  PubMed  CAS  Google Scholar 

  31. Knopp RH, Tsunehara C, Retzlaff BM, et al.: Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006, 55:1697–1703.

    Article  PubMed  CAS  Google Scholar 

  32. Farnier M, Roth E, Gil-Extremera B, et al.: Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007, 153:335.e1–335.e8.

    Article  Google Scholar 

  33. Ziajka P: Role of low-density lipoprotein apheresis. Am J Cardiol 2005, 96(4 Suppl 1):67–69.

    Article  Google Scholar 

  34. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR: Statinrelated adverse events: a meta-analysis. Clin Ther 2006, 28:26–35.

    Article  PubMed  CAS  Google Scholar 

  35. Davidson M, Clark J, Glass L, Kanumalla A: Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006, 97(Suppl 1):32C–43C.

    Article  PubMed  CAS  Google Scholar 

  36. Davidson MH: Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004, 3:547–557.

    Article  PubMed  CAS  Google Scholar 

  37. Kasiske B, Wanner C, O’Neil C: An assessment of statin safety by nephrologists. Am J Cardiol 2006, 97(8 Suppl A):82C–85C.

    Article  PubMed  CAS  Google Scholar 

  38. Davidson MH, Maccubbin D, Stepanavage M, et al.: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006, 97:223–228.

    Article  PubMed  CAS  Google Scholar 

  39. Davidson MH, Ballantyne CM, Kerzner B, et al.: Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004, 58:746–755.

    Article  PubMed  CAS  Google Scholar 

  40. Ballantyne CM, Davidson MH, McKenney J, et al.: Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study). Am J Cardiol 2008, 101:1428–1436.

    Article  PubMed  CAS  Google Scholar 

  41. Guyton JR, Bays HE: Safety considerations with niacin therapy. Am J Cardiol 2007, 99(6 Suppl 1):S22–S31.

    Article  Google Scholar 

  42. Zocor (simvastatin) [package insert]. Whitehouse Station, NJ: Merck & Co.; 2008. Available at http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf. Accessed June 2008.

  43. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering [no authors listed]. JAMA 1984, 251:365–374.

  44. Jacobson TA, Armani A, McKenney JM, Guyton JR: Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007, 99(6 Suppl 1):S47–S55.

    Article  Google Scholar 

  45. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97(8 Suppl 1):S52–S60.

    Article  Google Scholar 

  46. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The FIELD study investigators [no authors listed]. Lancet 2005, 366:1849–1861.

  47. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations with fibrate therapy. Am J Cardiol 2007, 99(6 Suppl 1):S3–S18.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lipid Research Clinic, 200 Hawkins Drive SE 226 GH, Iowa City, IA, 52242, USA

    Jennifer G. Robinson

Authors
  1. Jennifer G. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer G. Robinson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, J.G. LDL reduction: How low should we go and is it safe?. Curr Cardiol Rep 10, 481–487 (2008). https://doi.org/10.1007/s11886-008-0076-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-008-0076-3

Keywords

Search

Navigation